Nuclidium has secured a U.S. patent for its proprietary copper-61 (Cu-61)-based theranostic platform for treating prostate-specific membrane antigen (PSMA)-positive tumors.
U.S. Patent No. 12,527,885 protects the Cu-61-based diagnostic as well as its use in combination with the copper-67 (Cu-67)-based therapeutic in a theranostic setting, the company said. It covers the composition of matter and methods of using Cu-61-NU101 in radioimaging, including PET and SPECT imaging of PSMA-positive tumors, as well as the subsequent combination with the therapeutic pair Cu-67-NU101.
Cu-61-NU101 is currently in clinical evaluation, according to Nuclidium.
